Inozyme Pharma, Inc.
Inozyme Pharma, Inc. (INZY) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001693011 · INZY · NASDAQ · as of Jun 10, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001693011 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Inozyme Pharma, Inc. (NASDAQ: INZY) has submitted 378 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001693011, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Inozyme Pharma, Inc.'s most comprehensive regulatory disclosure. The most recent Inozyme Pharma, Inc. 10-K was filed on 2025-03-10 for fiscal year ending 2025. Historical INZY 10-K annual reports are available from 2017 through 2025.
Investors researching Inozyme Pharma, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
INZY SEC Filings · 8 questionsInozyme Pharma, Inc. (INZY) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 378 filings and access original documents at no cost. Inozyme Pharma, Inc.'s CIK is 0001693011.